Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCS-100 in Chronic Lymphocytic Leukemia
NCT00514696Phase 2Completed
- Sponsor
- La Jolla Pharmaceutical Company
- Start
- Feb 2007
- Primary completion
- Apr 2009
- Countries
- 1
01
Overview
Phase 2, open-label trial of GCS-100 in chronic lymphocytic leukemia (CLL), sponsored by La Jolla Pharmaceutical Company. Primary endpoint: Markers of apoptosis. Started Feb 2007; status: completed.
02
Drugs
GCS-100
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00514696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00514696.